{"prompt": "['8. Participation in an interventional clinical study with any investigational product (drug,', 'biologic, device etc.) within 4 weeks prior to Screening (Visit 1)', '9. Unable to:', '10. walk unassisted, and', '11. stand as needed for duplex ultrasound measurements of vein at scheduled visits', '12. Previous superficial thrombophlebitis of the target saphenous vein with scarring in the', 'treatment section', '13. Female patients of childbearing potential with a positive result from a pregnancy test', 'performed at Screening (Visit 1), Baseline (Visit 2), or Day of Treatment (Visit 3)', '14. Known sensitivity or allergic response to:', '15. sodium tetradecyl sulfate (STS) or any of its ingredients; and', '16. other products if planned for use on the study patient and there is no available alternative, e.g.,', 'local anesthetic; latex stockings, or gloves', '17. Known history of anaphylaxis or presence of multiple severe allergies', '18. Known high risk of thrombosis, e.g., two or more risk factors including, current use of', 'hormonal contraception, current use of hormone replacement therapy, extended periods of', 'immobility, cancer, obesity, recent trauma', '19. Known history of deep vein thrombus (DVT) or pulmonary embolism (PE), known history of', 'acute superficial vein thrombus, known hypercoagulable condition, post thrombotic syndrome', '20. Known history of drug or alcohol abuse within 2 years of Screening (Visit 1); and/or current', 'chronic narcotic usage, including for pain (e.g., opioids)', '21. Presence of tortuous target saphenous vein, which in the opinion of the Investigator will limit', 'vascular access and/or require more than one access site to treat patient', '22. Varicosities caused by known pelvic or abdominal pathology', '23. Lymphedema', '24. Fibromyalgia', '25. Other medical conditions or comorbidities which, in the opinion of the Investigator, could', 'interfere with study compliance, could affect the efficacy of treatment or could compromise', 'patient care, or could interfere with data interpretation, including, but not restricted to any one', 'of the following:', 'a. severe illness', 'b. edema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal', 'insufficiency, etc.)', 'c. documented human immunodeficiency virus (HIV)', 'd. congestive heart failure, coronary artery disease, cerebral vascular disease', 'e. active infection, tuberculosis, or sepsis', 'f.', 'active cancer or neoplasm (excluding non-melanoma skin cancer)', 'g. uncontrolled systemic disease such as diabetes mellitus, toxic hyperthyroidism, blood', 'dyscrasias, or acute respiratory (e.g., asthma), or skin diseases', 'Page 12 of 101'][\"26. Any patient that, in the Investigator's opinion, would be unlikely to receive clinical benefit\", 'from the study procedure', 'Efficacy Assessment (Primary, Secondary, Tertiary, Exploratory)', 'European Quality of Life scale (EQ-5D-5L)', 'VEINES-QOL/Sym', 'VAS score', 'CEAP', 'rVCSS', 'Ultrasound', 'Safety Assessment', 'Assessment of adverse events', 'Data Analysis', \"The study data will be analyzed and reported based on all patients' data from baseline up to the time\", 'when all patients have completed the Week 12 post-treatment follow-up visit or have discontinued', 'from the study. If a patient has discontinued from the study, the Last Observation will be carried', 'forward (LOCF) for analysis.', 'Page 13 of 101']\n\n###\n\n", "completion": "END"}